USANA Health Sciences, Inc. $USNA Holdings Boosted by Pzena Investment Management LLC

Key Points

• Pzena Investment Management LLC increased its stake in USANA Health Sciences by 9.4% during the second quarter, now holding over 1.19 million shares worth approximately $36.58 million.
• USANA's shares opened at $20.22, with a 52-week range between $20.10 and $41.83, showing a market capitalization of $369.42 million.
• Recent analyst ratings reflect a trend of downgrades for USANA, with Weiss Ratings issuing a "sell" and Zacks lowering its rating from "strong-buy" to "hold".

Pzena Investment Management LLC raised its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 9.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,198,260 shares of the company's stock after purchasing an additional 103,074 shares during the quarter. Pzena Investment Management LLC owned 6.44% of USANA Health Sciences worth $36,583,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of USNA. GAMMA Investing LLC grew its holdings in shares of USANA Health Sciences by 49,082.4% during the first quarter. GAMMA Investing LLC now owns 8,361 shares of the company's stock valued at $225,000 after buying an additional 8,344 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in USANA Health Sciences by 7.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,184 shares of the company's stock worth $248,000 after acquiring an additional 606 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its position in USANA Health Sciences by 27.1% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 18,223 shares of the company's stock worth $491,000 after acquiring an additional 3,887 shares during the period. Teacher Retirement System of Texas purchased a new position in USANA Health Sciences during the 1st quarter valued at about $888,000. Finally, Principal Financial Group Inc. increased its holdings in shares of USANA Health Sciences by 2.7% in the 1st quarter. Principal Financial Group Inc. now owns 55,076 shares of the company's stock valued at $1,485,000 after purchasing an additional 1,473 shares during the period. Institutional investors and hedge funds own 54.25% of the company's stock.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,058 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider David Mulham Mulham sold 3,515 shares of the company's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the sale, the insider owned 9,260 shares of the company's stock, valued at $280,207.60. This trade represents a 27.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.63% of the stock is currently owned by corporate insiders.

USANA Health Sciences Stock Performance

Shares of NYSE USNA opened at $20.22 on Monday. The business's 50-day simple moving average is $29.63 and its 200-day simple moving average is $29.31. USANA Health Sciences, Inc. has a 52 week low of $20.10 and a 52 week high of $41.83. The firm has a market cap of $369.42 million, a price-to-earnings ratio of 11.23, a P/E/G ratio of 0.64 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. USANA Health Sciences had a return on equity of 9.48% and a net margin of 3.79%.The firm had revenue of $200.22 million during the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. As a group, equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

USNA has been the subject of a number of research analyst reports. Weiss Ratings reissued a "sell (d+)" rating on shares of USANA Health Sciences in a research report on Wednesday, October 8th. Zacks Research downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 22nd. Finally, Wall Street Zen lowered shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, USANA Health Sciences has an average rating of "Reduce" and an average price target of $36.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.